ITMCTR2000003654尚未招募未知
A randomized, double-blind, placebo-controlled, placebo-controlled trial for Jiawei Zhichan Decoction for the treatment of sleep disorders in Parkinson's disease
适应症
试验速览
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 40 至 85（—）
- 性别
- All
入选标准
- •1. In line with the diagnostic criteria of Western medicine for Parkinson's disease;
- •2. Aged between 40 to 85 years old;
- •3. In accordance with the diagnostic criteria of western medicine for sleep disorders, or PDSS in any one score < 5 is classified as sleep disorders;
- •4. In line with the diagnostic criteria of TCM fibrillation syndrome of liver-kidney Yin deficiency;
- •5. Improved Hoehn-Yahr grading <=3;
- •6. Those who sign the informed consent.
排除标准
- •1. Patients with severe heart failure, renal failure, abnormal liver function, etc. that affect the curative effect evaluation of this disease;
- •2. Mental illness, epilepsy, pregnant women and lactating women;
- •3. People with aphasia, deaf-mute or severe cognitive impairment;
- •4. Patients with Parkinson's syndrome and Parkinson's superposition syndrome;
- •5. Participants in other clinical trials within 2 months.
研究者
相似试验
进行中（未招募）
1 期
Study of a new therapeutic agent used to treat portopulmonary hypertensioPortopulmonary hypertensionMedDRA version: 20.0Level: PTClassification code 10067281Term: Portopulmonary hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2014-004624-21-CZACTELION Pharmaceuticals Ltd.84
进行中（未招募）
1 期
A study to test the efficacy and safety of SAR442970 in adults with hidradenitis suppurativaMedDRA version: 20.0Level: LLTClassification code: 10020041Term: Hidradenitis suppurativa Class: 10040785Hidradenitis suppurativaCTIS2022-502370-17-00Sanofi-Aventis Research & Development84
进行中（未招募）
1 期
Study of a new therapeutic agent used to treat portopulmonary hypertensioPortopulmonary hypertensionMedDRA version: 18.0 Level: PT Classification code 10067281 Term: Portopulmonary hypertension System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2014-004624-21-FRACTELION Pharmaceuticals Ltd.85
进行中（未招募）
1 期
Dupilumab tested in cholinergic urticaria patientsCholinergic urticaria despite H1-antihistamine treatmentEUCTR2017-001262-25-DECharité - Universitätsmedizin Berlin72
进行中（未招募）
1 期
Study of a new therapeutic agent used to treat portopulmonary hypertensioPortopulmonary hypertensionMedDRA version: 20.0 Level: PT Classification code 10067281 Term: Portopulmonary hypertension System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2014-004624-21-DEACTELION Pharmaceuticals Ltd.85